Karyopharm to Report Second Quarter 2026 Financial Results on August 13, 2026

Rhea-AI Summary

Karyopharm Therapeutics (Nasdaq: KPTI) announced it will report its second quarter 2026 financial results on Thursday, August 13, 2026. The company’s management will host a conference call and live audio webcast at 8:00 a.m. ET the same day to review results and provide company updates.

Investors can join the call by dialing (800) 836-8184 (local) or (646) 357-8785 (international) at least 10 minutes before the start and requesting the Karyopharm Therapeutics call. A live webcast with slides will be available under “Events & Presentations” in the investor section of the company’s website, with an archived replay accessible about two hours after the event.

Market Context

KPTI's current short-interest signal was classified as high. This scheduled earnings report establis...

Analysis

KPTI's current short-interest signal was classified as high. This scheduled earnings report establishes an information checkpoint, while recent insider activity showed net selling and the active S-3 provides additional resale-registration context.

Key Figures

Reporting period: Q2 2026 Results date: August 13, 2026 Conference call time: 8:00 a.m. ET

3 metrics

Reporting period Q2 2026 Financial results to be reported

Results date August 13, 2026 Scheduled reporting date

Conference call time 8:00 a.m. ET August 13, 2026 conference call and webcast

Previous Earnings date Reports

2 past events · Latest: May 07 (Neutral)

Same Type Pattern 2 events

Date	Event	Sentiment	24h Move	Catalyst
May 07	earnings date notice	Neutral	-1.9%	Scheduled first-quarter 2026 results and an 8:00 a.m. ET conference call
Feb 05	earnings date notice	Neutral	-3.3%	Scheduled fourth-quarter and full-year 2025 results with an investor webcast

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Both prior earnings-date notices were followed by negative 24-hour reactions of -1.88% and -3.33%.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

-- Conference Call Scheduled for Thursday, August 13, 2026, at 8:00 a.m. ET --

NEWTON, Mass., Aug. 10, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will report second quarter 2026 financial results on Thursday, August 13, 2026. Karyopharm's management team will host a conference call and audio webcast at 8:00 a.m. ET on Thursday, August 13, 2026, to discuss the financial results and other company updates.

To access the conference call, please dial (800) 836-8184 (local) or (646) 357-8785 (international) at least 10 minutes prior to the start time and ask to be joined into the Karyopharm Therapeutics call. A live audio webcast of the call, along with accompanying slides, will be available under "Events & Presentations" in the Investor section of the Company's website, http://investors.karyopharm.com/events-presentations. An archived webcast will be available on the Company's website approximately two hours after the event.

About Karyopharm Therapeutics

Karyopharm Therapeutics is a commercial-stage pharmaceutical company pioneering the science of nuclear export inhibition to develop differentiated therapies for patients with cancer. The Company's lead therapy, XPOVIO^® (selinexor), is a first-in-class inhibitor of exportin 1 (XPO1). XPOVIO is marketed by the Company in the U.S. for adults with relapsed or refractory multiple myeloma and is approved as XPOVIO or NEXPOVIO® in more than 50 ex-U.S. countries and territories. Building on its leadership in XPO1 biology, Karyopharm is advancing selinexor's potential in hematological cancers, including in myelofibrosis. The Company is also exploring opportunities to evaluate XPO1 inhibition across myeloproliferative neoplasms using next-generation compounds, including eltanexor. Headquartered in Newton, Massachusetts, Karyopharm has an established, efficient, and scalable commercial infrastructure to bring novel therapeutic options to patients with cancer. For more information about our people, science and pipeline, please visit www.karyopharm.com, and follow us on LinkedIn and on X at @Karyopharm.

XPOVIO^® and NEXPOVIO^® are registered trademarks of Karyopharm Therapeutics Inc.

View original content to download multimedia:https://www.prnewswire.com/news-releases/karyopharm-to-report-second-quarter-2026-financial-results-on-august-13-2026-302845213.html

SOURCE Karyopharm Therapeutics Inc.

FAQ

When will Karyopharm (KPTI) report its Q2 2026 financial results?

Karyopharm plans to report its Q2 2026 financial results on Thursday, August 13, 2026. According to the company, the release will be accompanied by a management conference call and webcast that morning to discuss the results and provide corporate updates.

What time is Karyopharm Therapeutics' Q2 2026 earnings conference call on August 13, 2026?

The Karyopharm Q2 2026 conference call is scheduled for 8:00 a.m. ET on August 13, 2026. According to Karyopharm, investors should dial in at least 10 minutes early and can also access a simultaneous live audio webcast with presentation slides.

How can investors access the Karyopharm (KPTI) Q2 2026 earnings call by phone?

Investors can join the Karyopharm Q2 2026 call by dialing (800) 836-8184 locally or (646) 357-8785 internationally. According to the company, callers should request the Karyopharm Therapeutics call and connect about 10 minutes before the 8:00 a.m. ET start time.

Where can I listen to the Karyopharm Q2 2026 earnings webcast and view slides?

The Q2 2026 earnings webcast will be available in the Investor section of Karyopharm’s website under “Events & Presentations”. According to Karyopharm, the live audio stream will include accompanying slides and be accessible to online viewers worldwide.

Will a replay of Karyopharm’s (KPTI) Q2 2026 earnings call be available for investors?

Yes, an archived webcast of the Q2 2026 earnings call will be available on Karyopharm’s website. According to the company, the replay should be accessible approximately two hours after the live event in the Investor section under Events & Presentations.

What topics will Karyopharm management discuss on the Q2 2026 earnings call?

Karyopharm management plans to discuss second quarter 2026 financial results and other company updates. According to the company, the August 13, 2026 call and webcast will review recent performance and provide additional context for investors following the financial release.